Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains-Reference-Cited by-同舟云学术

Telavancin Is Active against Experimental Aortic Valve Endocarditis Caused by Daptomycin- and Methicillin-Resistant Staphylococcus aureus Strains

Published:2017-02 Issue:2 Volume:61 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Abdelhady Wessam¹,Bayer Arnold S.¹²³,Gonzales Rachelle¹,Li Liang¹,Xiong Yan Q.¹²³

Affiliation:

1. Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, California, USA

2. Division of Infectious Diseases, LAC Harbor-UCLA Medical Center, Torrance, California, USA

3. David Geffen School of Medicine at UCLA, Los Angeles, California, USA

Abstract

ABSTRACT We compared the efficacy of telavancin (TLV) and daptomycin (DAP) in an experimental rabbit endocarditis model caused by two clinically derived daptomycin-resistant (DAP r ) methicillin-resistant Staphylococcus aureus (MRSA) strains. TLV treatment significantly reduced MRSA densities in all target tissues and increased the percentage of these organs rendered culture negative compared to those with the untreated control or DAP-treated animals. These results demonstrate that TLV has potent in vivo efficacy against DAP r MRSA isolates in this invasive endovascular infection model.

Funder

Theravance Biopharma Antibiotics, Inc

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01877-16

Reference20 articles.

1. Risk Factors For Hematogenous Complications of Intravascular Catheter--Associated Staphylococcus aureus Bacteremia

2. Waves of resistance: Staphylococcus aureus in the antibiotic era

3. Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus